Creganna-Tactx Medical CEO Helen Ryan is preparing to pass the torch after 8 years in the corner office, with Abbott (NYSE:ABT) executive Robert "Chip" Hance slated to take the helm in September.
Abbott
MassDevice.com Q&A: James Mazzo on his move to Versant Ventures
James Mazzo has put 35 years into the optics and ophthalmology business, so it was no surprise that he got involved with AcuFocus and its device for treating presbyopia. Mazzo, who stepped down from leading Abbott Medical Optics earlier this year, added another title to his resume that’s more of a departure: He’s the 1st "operating partner" at Versant Ventures.
Abbott lands FDA nod for its FreeStyle Precision Pro monitoring system
Second Sight eyes $10M funding round | Wall Street Beat
Second Sight Medical is hoping to raise $10.5 million, according to a regulatory filing, as it brings its "bionic eye" Argus II retinal implant to the U.S. market.
The device, comprised of an eyeglass-mounted camera and an electrical stimulator implanted in the eye, works by converting video images captured by a miniature camera housed in the patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.
Abbott’s Q2 sales tick up, earnings beat Wall Street
Abbott acquires IDEV Technologies, OptiMedica
Abbott (NYSE:ABT) said it agreed to acquire a pair of companies in the peripheral stent and ophthalmic space for a total of up to $710 million.
The Chicago-ares medical device company said it inked a deal worth $310 million for Webster, Texas-based IDEV Technologies and its Supera Veritas stent for treating peripheral artery disease.
Abbott touts another win for its Xience Xpedition drug-eluting stents
Stent wars: Researchers report a tie, of sorts, for Medtronic’s Resolute and Abbott’s Xience V DES
Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.